Abstract: Provided are a preparation of semicarbazide-sensitive amine oxidase inhibitor and the use thereof. In particular, disclosed are a compound as shown in formula I, or a stereoisomer or racemate or pharmaceutically acceptable salt thereof. Also disclosed is that the above-mentioned compound can inhibit semicarbazide-sensitive amine oxidase.

Abstract: Provided are a JAK kinase inhibitor, preparation and use thereof. In particular, provided is a compound of Formula I, wherein each group is as described in the specification. The compound has an excellent JAK inhibitory activity, and therefore can be used to prepare pharmaceutical compositions for the treatment of cancer and other diseases related to JAK activity.

Abstract: This application discloses a method for processing group information. When an upper limit of a number of people in a target group needs to be expanded, an expansion request is transmitted based on triggering by a first user on the target group. The expansion request includes an identification of the target group, and the expansion request is configured to request for expanding an upper limit of a number of group members of the target group. A second user with expansion permission may configure the upper limit of the number of the target group based on the expansion request. In response to a configuration by the second user on the target group, an expansion response is transmitted to a client of the first user, where the expansion response is configured to indicate a result of expansion on the target group.

Abstract: This application discloses a method for processing group information. When an upper limit of a number of people in a target group needs to be expanded, an expansion request is transmitted based on triggering by a first user on the target group. The expansion request includes an identification of the target group, and the expansion request is configured to request for expanding an upper limit of a number of group members of the target group. A second user with expansion permission may configure the upper limit of the number of the target group based on the expansion request. In response to a configuration by the second user on the target group, an expansion response is transmitted to a client of the first user, where the expansion response is configured to indicate a result of expansion on the target group.

Abstract: The present invention relates to a strategy for combining a berberine analog with a JAK inhibitor in the treatment of inflammatory diseases of the gastrointestinal tract. Specifically, provided by the present invention is a pharmaceutical composition containing the berberine analog and the JAK inhibitor, and a use thereof in the treatment of inflammatory diseases of the gastrointestinal tract. The composition may exhibit an improved effect over the use of berberine or the JAK inhibitor alone.

Abstract: The present invention relates to a codrug that cleaved in the gut, preparation therefor, and a use thereof. Specifically, provided is a codrug compound in formula I. Also provided are a method of using the present compound for the treatment of gastrointestinal tract autoimmune diseases, inflammatory diseases, and cancers, as well as a method and an intermediate for preparing the present compound.

Abstract: The present invention provides preparation of a semicarbazide-sensitive amine oxidase inhibitor and use thereof. In particular, disclosed in the present invention are a compound as represented by formula I, or a stereoisomer or a racemate or a pharmaceutically acceptable salt of the compound. Also disclosed in the present invention is that the compound can inhibit semicarbazide-sensitive amine oxidase.

Abstract: Provided are a preparation of semicarbazide-sensitive amine oxidase inhibitor and the use thereof. In particular, disclosed are a compound as shown in formula I, or a stereoisomer or racemate or pharmaceutically acceptable salt thereof. Also disclosed is that the above-mentioned compound can inhibit semicarbazide-sensitive amine oxidase.

Abstract: Provided are a JAK kinase inhibitor, preparation and use thereof. In particular, provided is a compound of Formula I, wherein each group is as described in the specification. The compound has an excellent JAK inhibitory activity, and therefore can be used to prepare pharmaceutical compositions for the treatment of cancer and other diseases related to JAK activity.